Curis

Curis Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Curis (CRIS) as of Nov 20, 2026 is 358.76 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 91.18 % — a change of 293.45% (higher).

Cash Conversion

358.76 %

YoY

293.45%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Curis is 2025 358.76 % . Cash Conversion Rate (OCF/Net Income) of Curis was 2024 91.18 % . It decreases by 293.45% higher compared to the previous year.

The Curis Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
92.29 USD
Jan 1, 2019
81.53 USD
Jan 1, 2020
86.06 USD
Jan 1, 2021
82.80 USD
Jan 1, 2022
90.08 USD
Jan 1, 2023
81.06 USD
Jan 1, 2024
91.18 USD
Jan 1, 2025
358.76 USD
The Curis Cash Conversion history
YEARCash ConversionYoY
358.76 %+293.45%
91.18 %+12.48%
81.06 %-10.01%
90.08 %+8.79%
82.80 %-3.79%
86.06 %+5.56%
81.53 %-11.66%
92.29 %+1.77%
90.69 %+52.99%
59.28 %+16.97%
50.68 %-43.55%
89.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Cash Conversion Rate (OCF/Net Income) of Curis is 358.76 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Curis changed from 91.18 % to 358.76 %, representing a 293.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Curis since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Curis with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curis

All Key Metrics — Curis